A venture capital firm targeting health tech opportunities has announced its latest fund.
Nina Capital has announced its second fund, which will be used to continue its strategy of investing exclusively in pre-seed to Series A healthcare technology companies based in Europe, the US and Israel.
Since launching in 2019, the firm built a portfolio of 23 early-stage healthcare technology companies for its inaugural EUR18Mfund, after screening more than 2600 businesses.
Several of the 23 companies—including Ultromics, Contextflow and EarlySight—raised subsequent funding from international investors, and Canadian health data company Replica Analytics was acquired by Aetion, a healthcare analytics company in New York and Barcelona.
“Our second fundraise validates that our market positioning is correct,” said Yahel Halamish, head of investor relations at Nina Capital.
Marc Subirats, general partner, added: “The venture capital industry is evolving such that the most successful firms either build huge, multi-stage generalist funds or focus on early-stage specialist funds. Nina Capital is well positioned to become the best recognised health tech specialist in the latter category.”
